anti nucleocapsid protein primary antibody cocktail  (EastCoast Bio)

Journal: ACS applied materials & interfaces

Article Title: Improved Recovery of Captured Airborne Bacteria and Viruses with Liquid-Coated Air Filters

doi: 10.1021/acsami.2c14754

Figure Lengend Snippet: HEPA liquid nets recover JCPyV and SARS-CoV-2: qRT-PCR. Values from the viral genomic material harvested from samples from n = 9 (JCPyV) or n = 6 (SARS-CoV-2) samples collected over three or two separate runs, respectively. A lower value indicates more genomic material present. Both the aqueous and fluorinated phases of the liquid used to recover JCPyV and SARS-CoV-2 from either dry control (HEPA controls) or liquid net (HEPA-LN) filter surfaces are given. Average Ct values are represented, with * signifying significance at P < 0.05,** significance at P < 0.001 and ***P < 0.001. Data represent triplicate samples for three (JCPyV) or two (SARS-CoV-2) independent experiments.

Article Snippet: Primary antibody against SARS-CoV-2 nucleocapsid (NP) (Sino Biological) (1:500) in PBS-T was added at 50 μ L/well at RT for 1 h. Wells were washed 3× with PBS-T for 5 min.

Techniques: Quantitative RT-PCR

Journal: ACS applied materials & interfaces

Article Title: Improved Recovery of Captured Airborne Bacteria and Viruses with Liquid-Coated Air Filters

doi: 10.1021/acsami.2c14754

Figure Lengend Snippet: HEPA-LNs recover JCPyV and SARS-CoV-2: infectivity. Qualitative (A) and quantitative (B) infectivity results from the samples presented in Figure 6. (A) Representative images at 20× illustrate infected cells (JCPyV in red, SARS-CoV-2 in green) and total cells (blue). (B) Average number of infected cells/20× field of view normalized to 100% of the control aqueous phase sample (JCPyV) or per well (SARS-CoV-2). Data represent triplicate samples for three (JCPyV) or two (SARS-CoV-2) independent experiments. Scale bars = 100 μm. **Signifies significance at P < 0.01.

Article Snippet: Primary antibody against SARS-CoV-2 nucleocapsid (NP) (Sino Biological) (1:500) in PBS-T was added at 50 μ L/well at RT for 1 h. Wells were washed 3× with PBS-T for 5 min.

Techniques: Infection

Journal: Pharmaceuticals

Article Title: Bacteriophage-Derived Double-Stranded RNA Exerts Anti-SARS-CoV-2 Activity In Vitro and in Golden Syrian Hamsters In Vivo

doi: 10.3390/ph15091053

Figure Lengend Snippet: The antiviral activity of Larifan against SARS-CoV-2 in vitro. ( A ) No significant cytotoxicity of Larifan observed in Calu3 cells or HSAEC done in triplicate. ( B ) Viral RNA copy number drop in Calu3 cell supernatants at day three post-infection when Larifan was present throughout the experiment (“full-time treatment”) or added pre- or post-infection and performed in duplicate. ( C ) Infectious SARS-CoV-2 titer drop in Calu3 cell supernatants in paired experiments in Vero E6 cells after treatment with Larifan at day three post-infection when Larifan was present throughout the experiment or added pre- or post-infection. ( D ) Viral RNA copy number drop in HSAEC when Larifan was present throughout and added pre- or post-infection performed in duplicate. Data presented as mean (±SD). Statistical significance analysis was performed by using Kruskal–Wallis tests with Dunn’s multiple comparison test. * p < 0.05, ** p < 0.01. ( E – G ) Representative pictures of SARS-CoV-2 NP (red) detection by immunocytochemistry in HSAEC upon treatment with 100 µg/mL Larifan. Nuclei are counterstained with DAPI. Scale bars 100 µm.

Article Snippet: Cells were then stained with SARS-CoV-2 NP primary antibody (Thermo Fisher, Waltham, US) overnight at 4 °C, then washed and stained with Alexa Fluor 594 conjugated secondary antibody (Abcam, Cambridge, UK).

Techniques: Activity Assay, In Vitro, Infection, Immunocytochemistry

Journal: Pharmaceuticals

Article Title: Bacteriophage-Derived Double-Stranded RNA Exerts Anti-SARS-CoV-2 Activity In Vitro and in Golden Syrian Hamsters In Vivo

doi: 10.3390/ph15091053

Figure Lengend Snippet: In vivo testing of Larifan’s effect in the SARS-CoV-2 infection model of golden Syrian hamsters. ( A ) Experimental strategy: hamsters were pre-treated with Larifan twice before virus infection, infected with SARS-CoV-2, and after infection treated two times more with Larifan always with an interval of 24 h between each administration. ( B ) Viral RNA copy number in the lungs of SARS-CoV-2 infected untreated and infected treated hamsters on days three and five after s.c. or i.n. Larifan administration. ( C ) Infectious virus titer in Vero E6 cells in the lungs of SARS-CoV-2-infected untreated and infected treated hamsters on days three and five after s.c. or i.n. Larifan administration. ( D ) Weight changes of SARS-CoV-2-infected untreated and infected Larifan-treated hamsters during the study. Data presented as mean (±SD). Statistical significance analysis was performed by using two-way ANOVA. * p < 0.05, ** p < 0.01. Dots represent individual hamsters.

Article Snippet: Cells were then stained with SARS-CoV-2 NP primary antibody (Thermo Fisher, Waltham, US) overnight at 4 °C, then washed and stained with Alexa Fluor 594 conjugated secondary antibody (Abcam, Cambridge, UK).

Techniques: In Vivo, Infection

Journal: Pharmaceuticals

Article Title: Bacteriophage-Derived Double-Stranded RNA Exerts Anti-SARS-CoV-2 Activity In Vitro and in Golden Syrian Hamsters In Vivo

doi: 10.3390/ph15091053

Figure Lengend Snippet: Larifan treatment reduces SARS-CoV-2 antigens in the lungs and improves lung histopathological features of infected animals. Representative immunohistopathology for SARS-CoV-2 NP (green) ( A – F ) and hematoxylin- and eosin-stained ( G – L ) images of lungs of infected and infected Larifan-treated hamsters. ( A ) Lungs of infected untreated hamster three days post-infection; immunoreactivity predominantly located in the bronchiolar epithelium. ( B ) Lungs of infected untreated hamster five days post-infection; immunoreactivity observed in different alveolar regions with patchy distribution pattern. ( C , D ) Lungs of infected and treated hamster three and five days after Larifan s.c. administration. ( E , F ) Lungs of infected and treated hamster three and five days after Larifan i.n. administration. ( G , H ) Lungs of infected untreated hamster three and five days post-infection: thickening of the interalveolar septa due to inflammatory infiltrate (blue arrow), vascular thrombosis (red arrow), alveolar septum fibrosis (black arrow), and signs of the bronchial epithelium hyperplasia (yellow arrow). ( I , J ) Lungs of infected and treated hamster three and five days after Larifan s.c. administration. ( K , L ) Lungs of infected and treated hamster three and five after Larifan i.n. administration. ( M ) The score of immunolabeled virus NP in lungs of infected untreated and infected Larifan-treated hamsters. ( N ) Histopathological damage severity score of hamster lungs of infected untreated and infected Larifan-treated animals. Data presented as mean. Statistical significance analysis was performed using Kruskal–Wallis tests with Dunn’s multiple comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001. Dots represent individual hamsters. Scale bars 100 µm.

Article Snippet: Cells were then stained with SARS-CoV-2 NP primary antibody (Thermo Fisher, Waltham, US) overnight at 4 °C, then washed and stained with Alexa Fluor 594 conjugated secondary antibody (Abcam, Cambridge, UK).

Techniques: Infection, Staining, Immunolabeling